Clinical Trial Update: Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Aldesleukin in participants with metastatic renal cell carcinoma or metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Renal Cell Carcinoma, Metastatic Melanoma | Phase 4 | Status: COMPLETED | Results posted: 2021-06-08